HBV Forum 5 was held in Vienna, Austria at the Messe Wien Exhibition Congress Center on April 10th, 2019.
Agenda
Participants
Presentations
Welcoming Remarks
Ryan Anderson, The Forum for Collaborative Research
HDV Therapy—Relevant Recent Findings and Suggested Endpoints
Jeffrey Glenn, Stanford University Medical Center
Molecular Insights into the Synergism Between the HBV/HDV Entry Inhibitor Myrcludex B and Interferon
Stephan Urban, University Hospital Heidelberg
Clinical Challenges in the Development of HDV Infection
Heiner Wedemeyer, Essen University Hospital
Association Between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-analysis
Ryan Anderson, The Forum for Collaborative Research
HBV Forum Immune Monitoring Working Group (IMWG)
Sara Ferrando-Martinez, AstraZeneca
Early Learnings from NUC Stop Studies
Bruce Given, Arrowhead Pharmaceuticals
Stopping NA Treatment
Harry Janssen, Toronto Centre for Liver Disease, University Health Network